News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
UniQure’s AMT-130 Receives FDA Breakthrough Therapy Designation for Huntington’s Disease
Saturday, April 19, 2025UniQure NV a biotechnology company focused on developing gene therapies for serious medical conditions has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to its gene therapy candidate AMT
Norgine Expands Rare Disease Portfolio with Acquisition of Theravia
Thursday, April 17, 2025Norgine has announced the acquisition of Theravia an international pharmaceutical company focused on treatments for rare and serious medical conditions This move aligns with Norgines strategy to grow its presence in the rare disease and specialty
Nurix Announces FDA Clearance for GS-6791/NX-0479, a Novel IRAK4 Degrader for Inflammatory Conditions
Thursday, April 17, 2025Nurix Therapeutics a clinicalstage biopharmaceutical company has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for GSNX
Leqembi® (lecanemab) Becomes First Approved Treatment in the EU to Slow Progression of Early Alzheimer’s Disease
Wednesday, April 16, 2025Eisai Co Ltd and Biogen Inc have announced that the European Commission has authorised the use of Leqembi lecanemab an amyloidbeta A monoclonal antibody for the treatment of earlystage Alzheimers disease AD in the European Union
Chromatin Bioscience Enters Collaboration Agreement with Astellas
Tuesday, April 15, 2025Chromatin Bioscience known for its work in developing synthetic promoters and gene control systems has entered into a collaboration agreement with Astellas Pharma a global company in the life sciences sector
Boehringer Ingelheim collaborates with Cue Biopharma to develop next-generation treatment for autoimmune and inflammatory diseases
Tuesday, April 15, 2025Boehringer Ingelheim has entered into a strategic research collaboration and licensing agreement with Cue Biopharma to develop and commercialise a potential new treatment CUE for autoimmune conditions
SynOx Therapeutics Granted Fast Track Designation by U.S. FDA for Emactuzumab in Treating Tenosynovial Giant Cell Tumours (TGCT)
Monday, April 14, 2025SynOx Therapeutics Limited a latestage clinical biopharmaceutical company has received Fast Track Designation FTD from the United States Food and Drug Administration FDA for its investigational therapy emactuzumab This designation applies to the trea...
Argenx Receives FDA Approval for VYVGART Hytrulo Prefilled Syringe for Self-Injection in gMG and CIDP
Friday, April 11, 2025Argenx SE a global immunology company focused on severe autoimmune conditions has received approval from the US Food and Drug Administration FDA for a new prefilled syringe version of VYVGART Hytrulo efgartigimod alfa and hyaluronidaseqvfc
Renovaro Completes Merger with BioSymetrics to Strengthen AI-Based Biomarker Discovery and Precision Medicine
Thursday, April 10, 2025Renovaro Biosciences Inc a TechBio company specialising in advanced diagnostics drug discovery and genetically enhanced cancer therapies has finalised its previously announced merger with BioSymetrics The transaction was completed on April
AmacaThera Forms Partnership with Global Pharmaceutical Company to Develop Long-Acting Biologic Using Hydrogel Platform
Wednesday, April 09, 2025AmacaThera a clinicalstage biotechnology company focused on drug delivery has entered into a new collaboration with a leading global pharmaceutical firm The partnership aims to develop a longacting singleinjection biologic using AmacaTheras proprieta...
